Nantahala Capital Management’s Gyre Therapeutics GYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-4,520
| Closed | -$32.7K | – | 118 |
|
|
2023
Q3 | $32.7K | Hold |
4,520
| – | – | ﹤0.01% | 110 |
|
|
2023
Q2 | $23.8K | Sell |
4,520
-6,175
| -58% | -$32.6K | ﹤0.01% | 107 |
|
|
2023
Q1 | $33.2K | Sell |
10,695
-47,712
| -82% | -$148K | ﹤0.01% | 107 |
|
|
2022
Q4 | $231K | Sell |
58,407
-282,224
| -83% | -$1.12M | 0.02% | 94 |
|
|
2022
Q3 | $1.29M | Sell |
340,631
-26,823
| -7% | -$101K | 0.08% | 71 |
|
|
2022
Q2 | $4.91M | Buy |
367,454
+44,682
| +14% | +$597K | 0.25% | 47 |
|
|
2022
Q1 | $1.6M | Sell |
322,772
-45,449
| -12% | -$225K | 0.07% | 79 |
|
|
2021
Q4 | $2.52M | Buy |
368,221
+43,926
| +14% | +$301K | 0.09% | 75 |
|
|
2021
Q3 | $10M | Sell |
324,295
-13,220
| -4% | -$407K | 0.32% | 44 |
|
|
2021
Q2 | $11M | Sell |
337,515
-3,996
| -1% | -$130K | 0.31% | 49 |
|
|
2021
Q1 | $12.9M | Buy |
341,511
+92,800
| +37% | +$3.51M | 0.38% | 41 |
|
|
2020
Q4 | $11.8M | Buy |
248,711
+5,811
| +2% | +$275K | 0.36% | 50 |
|
|
2020
Q3 | $7.83M | Hold |
242,900
| – | – | 0.24% | 58 |
|
|
2020
Q2 | $10.7M | Buy |
242,900
+50,000
| +26% | +$2.2M | 0.32% | 43 |
|
|
2020
Q1 | $6.32M | Buy |
192,900
+50,000
| +35% | +$1.64M | 0.24% | 46 |
|
|
2019
Q4 | $7.3M | Buy |
142,900
+1,188
| +0.8% | +$60.7K | 0.22% | 42 |
|
|
2019
Q3 | $5.22M | Buy |
141,712
+2,666
| +2% | +$98.2K | 0.19% | 53 |
|
|
2019
Q2 | $7.69M | Buy |
139,046
+11,280
| +9% | +$624K | 0.24% | 43 |
|
|
2019
Q1 | $7.77M | Buy |
127,766
+13,734
| +12% | +$835K | 0.24% | 44 |
|
|
2018
Q4 | $6.75M | Buy |
+114,032
| New | +$6.75M | 0.21% | 50 |
|